PHRM 4060 Exam III Study Guide
Bile Acid Resins - Answer -Lowers plasma LDL levels by *indirectly increasing rate of
LDL clearance from bloodstream*
-*MOA*: Binds to bile acids and increases fecal excretion of bile acids, decreasing the
amount of bile acids returning to the liver. *Stops feedback inhibition of
7alpha-hydroxylase* and increases conversion of cholesterol to bile acids
-*Secondary MOA*: Decreases hepatic cholesterol which increases LDL receptor
expression, uptake of plasma LDL, induces HMG-CoA reductase, and increases
biosynthesis of cholesterol.
-*Structure*: Polymeric resin with crosslinking agent. *Positive charge from substituted
amine acts as binding sites for bile acids*
-*Adverse effects*: *Minimal side effects* due to lack of oral absorption; constipation,
increased frequency of loose stools due to higher fat excretion, hypoprothrombinemia,
bleeding
-*Drug Interactions*: can potentially decrease oral absorption of almost any other drug.
*All oral meds should be taken 1 hour before or 4 hours after taking bile acids*. Can
interact with warfarin.
HMG-CoA Reductase Inhibitors (Statins) - Answer -*MOA*: Blocks conversion of
HMG-CoA to mevalonic acid, decreasing cholesterol synthesis. Causes increased
expression of HMG-CoA reductase and LDL receptors. *Enhanced LDL receptor
expression and LDL uptake is primary mechanism for lowering LDL levels*.
-*Adverse effects*: GI disturbances, increase in CK levels, myalgia, myopathy.
Rhabdomyolysis is rare.
-*Drug interactions*: Increased risk of myopathy with 3A4 inhibitors
Natural/semi-synthetic statins - Answer -Lovastatin (lactone/inactive prodrug form);
primarily metabolized by CYP3A4
-Pravastatin: *Not* metabolized by CYP3A4
-Simvastatin (lactone/inactive prodrug form); primarily metabolized by CYP3A4
Synthetic statins - Answer -Fluvastatin: metabolized by 2C9
-Atorvastatin: metabolized by 3A4
-Pitavastatin: metabolized mostly by 2C9 and undergoes lactonization
-Rosuvastatin: partly metabolized by 2C9
,Which statins are prodrugs? - Answer lovastatin and simvastatin
Which statins are not metabolized by CYP3A4? - Answer -Pravastatin
-Pitavastatin (2C9 and lactonization)
-Rosuvastatin (2C9)
-Fluvastatin *mostly* 2C9 but some 3A4
What drugs are of concern when taking statins? - Answer 3A4 inhibitors including:
-Cyclosporine
-Azole antifungals
-Macrolides (erythromycin, clarithromycin)
-HIV protease inhibitors
-Nefazodone
-Grapefruit juice
-Verapamil
PCSK9 Inhibitors - Answer Evolocumab (Repatha), Alirocumab (Praluent)
-*MOA*: Inhibits PCSK9 that binds to LDL-receptors, *preventing degradation of LDL
receptors and increasing expression of LDL receptors on surface of hepatocytes*,
lowering plasma LDL-C
-*Indication*: Patients with very high cholesterol levels (500-600 mg/dL), patients with
mixed hyperlipidemia or hypercholesterolemia in conjunction with diet and/or statins
Cholesterol Transport Inhibitors - Answer Ezetimibe (Zetia)
-*MOA*: Lowers plasma cholesterol by inhibiting cholesterol absorption in small
intestines. *Binds transport protein* to reduce cholesterol transport and absorption,
while not interfering with the absorption of other compounds. Decrease in cholesterol
causes *increase in cholesterol biosynthesis and overall LDL-lowering*.
-*Indication*: Can be used alone or in conjunction with statin for patients that don't
respond to diet, exercise, or other non-pharmacologic regimens.
-*Metabolism*: rapidly and extensively metabolized in intestinal wall and liver to
glucuronide. Major metabolite is active compound that is excreted in bile and undergoes
enterohepatic recirculation.
-*Adverse effects*: well tolerated; abdominal pain, diarrhea, cramping, fatigue, back
pain.
, Fibric Acid Derivatives - Answer Fibrates
-*MOA*: *Decrease plasma triglycerides* more than cholesterol. Significant decrease in
VLDL, increase in HDL. *Binds to and activates PPAR-alpha* which stimulates fatty acid
oxidation (lowering VLDL) and stimulates lipoprotein lipase (*removing triglycerides
from plasma VLDL*). Also increases turnover and removal of cholesterol from liver, thus
increasing biliary secretion of cholesterol and fecal excretion.
-*Metabolism*: Prodrugs have to undergo hydrolysis to active metabolite. Others are
already in active form or the active metabolites of prodrugs undergo oxidation or
conjugation to be deactivated.
-*Adverse effects*: Well tolerated; myopathy, myositis, rhabdomyolysis, increased risk
of gallstones due to increased excretion of cholesterol, increased hypoprothrombinemic
effect with anticoagulants. *Chlorofibrate* has higher morbidity and mortality,
malignancy, gallbladder disease, pancreatitis.
Which fibrates are prodrugs? - Answer -Fenofibrate
-Chlorofibrate
Nicotinic Acid - Answer Niacin
-Vitamin B3 (water-soluble) necessary for synthesis of NAD+ and NADP+
-*MOA*: Inhibits lipidolysis, decreasing mobilization of free fatty acids and reducing
delivery of fatty acids to the liver. This *reduces hepatic triglyceride synthesis, lowering
VLDL and LDL*. Also reduces clearance of apolipoproteinA-I which increases HDL
levels.
-*Adverse effects*: cutaneous vasodilation, GI intolerance, hepatic dysfunction and
hepatic toxicity. *Avoid use in patients with hepatic disease or peptic ulcer disease*,
caution in patients with diabetes or gout.
Different types of hemophilia - Answer -Hemophilia A: factor VIII deficiency
-Hemophilia B: factor IX deficiency
-Acquired hemophilia: autoantibody against VIII
*All ultimately cause inadequate thrombin levels*
Original Hemophilia Therapeutics - Answer -Plasma transfusions
-Cryoprecipitate factor VIII
-Lyophilized factor IX
-Mononine (factor IX)
-NovoSeven (rFactor VIIa)
Bile Acid Resins - Answer -Lowers plasma LDL levels by *indirectly increasing rate of
LDL clearance from bloodstream*
-*MOA*: Binds to bile acids and increases fecal excretion of bile acids, decreasing the
amount of bile acids returning to the liver. *Stops feedback inhibition of
7alpha-hydroxylase* and increases conversion of cholesterol to bile acids
-*Secondary MOA*: Decreases hepatic cholesterol which increases LDL receptor
expression, uptake of plasma LDL, induces HMG-CoA reductase, and increases
biosynthesis of cholesterol.
-*Structure*: Polymeric resin with crosslinking agent. *Positive charge from substituted
amine acts as binding sites for bile acids*
-*Adverse effects*: *Minimal side effects* due to lack of oral absorption; constipation,
increased frequency of loose stools due to higher fat excretion, hypoprothrombinemia,
bleeding
-*Drug Interactions*: can potentially decrease oral absorption of almost any other drug.
*All oral meds should be taken 1 hour before or 4 hours after taking bile acids*. Can
interact with warfarin.
HMG-CoA Reductase Inhibitors (Statins) - Answer -*MOA*: Blocks conversion of
HMG-CoA to mevalonic acid, decreasing cholesterol synthesis. Causes increased
expression of HMG-CoA reductase and LDL receptors. *Enhanced LDL receptor
expression and LDL uptake is primary mechanism for lowering LDL levels*.
-*Adverse effects*: GI disturbances, increase in CK levels, myalgia, myopathy.
Rhabdomyolysis is rare.
-*Drug interactions*: Increased risk of myopathy with 3A4 inhibitors
Natural/semi-synthetic statins - Answer -Lovastatin (lactone/inactive prodrug form);
primarily metabolized by CYP3A4
-Pravastatin: *Not* metabolized by CYP3A4
-Simvastatin (lactone/inactive prodrug form); primarily metabolized by CYP3A4
Synthetic statins - Answer -Fluvastatin: metabolized by 2C9
-Atorvastatin: metabolized by 3A4
-Pitavastatin: metabolized mostly by 2C9 and undergoes lactonization
-Rosuvastatin: partly metabolized by 2C9
,Which statins are prodrugs? - Answer lovastatin and simvastatin
Which statins are not metabolized by CYP3A4? - Answer -Pravastatin
-Pitavastatin (2C9 and lactonization)
-Rosuvastatin (2C9)
-Fluvastatin *mostly* 2C9 but some 3A4
What drugs are of concern when taking statins? - Answer 3A4 inhibitors including:
-Cyclosporine
-Azole antifungals
-Macrolides (erythromycin, clarithromycin)
-HIV protease inhibitors
-Nefazodone
-Grapefruit juice
-Verapamil
PCSK9 Inhibitors - Answer Evolocumab (Repatha), Alirocumab (Praluent)
-*MOA*: Inhibits PCSK9 that binds to LDL-receptors, *preventing degradation of LDL
receptors and increasing expression of LDL receptors on surface of hepatocytes*,
lowering plasma LDL-C
-*Indication*: Patients with very high cholesterol levels (500-600 mg/dL), patients with
mixed hyperlipidemia or hypercholesterolemia in conjunction with diet and/or statins
Cholesterol Transport Inhibitors - Answer Ezetimibe (Zetia)
-*MOA*: Lowers plasma cholesterol by inhibiting cholesterol absorption in small
intestines. *Binds transport protein* to reduce cholesterol transport and absorption,
while not interfering with the absorption of other compounds. Decrease in cholesterol
causes *increase in cholesterol biosynthesis and overall LDL-lowering*.
-*Indication*: Can be used alone or in conjunction with statin for patients that don't
respond to diet, exercise, or other non-pharmacologic regimens.
-*Metabolism*: rapidly and extensively metabolized in intestinal wall and liver to
glucuronide. Major metabolite is active compound that is excreted in bile and undergoes
enterohepatic recirculation.
-*Adverse effects*: well tolerated; abdominal pain, diarrhea, cramping, fatigue, back
pain.
, Fibric Acid Derivatives - Answer Fibrates
-*MOA*: *Decrease plasma triglycerides* more than cholesterol. Significant decrease in
VLDL, increase in HDL. *Binds to and activates PPAR-alpha* which stimulates fatty acid
oxidation (lowering VLDL) and stimulates lipoprotein lipase (*removing triglycerides
from plasma VLDL*). Also increases turnover and removal of cholesterol from liver, thus
increasing biliary secretion of cholesterol and fecal excretion.
-*Metabolism*: Prodrugs have to undergo hydrolysis to active metabolite. Others are
already in active form or the active metabolites of prodrugs undergo oxidation or
conjugation to be deactivated.
-*Adverse effects*: Well tolerated; myopathy, myositis, rhabdomyolysis, increased risk
of gallstones due to increased excretion of cholesterol, increased hypoprothrombinemic
effect with anticoagulants. *Chlorofibrate* has higher morbidity and mortality,
malignancy, gallbladder disease, pancreatitis.
Which fibrates are prodrugs? - Answer -Fenofibrate
-Chlorofibrate
Nicotinic Acid - Answer Niacin
-Vitamin B3 (water-soluble) necessary for synthesis of NAD+ and NADP+
-*MOA*: Inhibits lipidolysis, decreasing mobilization of free fatty acids and reducing
delivery of fatty acids to the liver. This *reduces hepatic triglyceride synthesis, lowering
VLDL and LDL*. Also reduces clearance of apolipoproteinA-I which increases HDL
levels.
-*Adverse effects*: cutaneous vasodilation, GI intolerance, hepatic dysfunction and
hepatic toxicity. *Avoid use in patients with hepatic disease or peptic ulcer disease*,
caution in patients with diabetes or gout.
Different types of hemophilia - Answer -Hemophilia A: factor VIII deficiency
-Hemophilia B: factor IX deficiency
-Acquired hemophilia: autoantibody against VIII
*All ultimately cause inadequate thrombin levels*
Original Hemophilia Therapeutics - Answer -Plasma transfusions
-Cryoprecipitate factor VIII
-Lyophilized factor IX
-Mononine (factor IX)
-NovoSeven (rFactor VIIa)